BOSTON ( TheStreet) -- Welcome to the doubleheader FDA advisory panel live blog: The morning panel features Aveo Oncology (AVEO - Get Report) and its kidney cancer drug tivozanib. In the afternoon session, Delcath Systems (DCTH - Get Report) brings the Melblez liver-tumor therapy in front of the FDA's outside experts.
The panel experts will consider the efficacy and safety of tivozanib and Melblez and vote to recommend approval -- or not. The final approval decision rests with the FDA.
Expect trading in both Aveo and Delcath to be halted during their respective panel sessions. Both stocks have been under pressure this week on FDA reviews which raised concerns and questions about the clinical benefit and/or safety of tivozanib and Melblez. It will be the job of Aveo and Delcath to counter these concerns and convince the panel members that their respective products deserve FDA approval.-- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts